CDK4/6 inhibitors in lung cancer: current practice and future directions
Lung cancer is the leading cause of cancer-related deaths worldwide, and ∼85% of lung cancers are classified as nonsmall cell lung cancer (NSCLC). These malignancies can proliferate indefinitely, in part due to dysregulation of the cell cycle and the resulting abnormal cell growth. The specific acti...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
European Respiratory Society
2024-02-01
|
Series: | European Respiratory Review |
Online Access: | http://err.ersjournals.com/content/33/171/230145.full |